are you talking about the oh so wonderful sanitiser that the company claimed would kill AIDS and tuberculosis
Retractions In announcement 1, Holista made the following statements. • “Path-Away®, a plant-based alcohol-free active ingredient that has proven to kill all previously tested corona-type viruses” • “Path-Away®, which has been tested and proven to kill more than 170 pathogens (including viruses, bacteria, and fungi), was developed by GICC LLC. It kills the AIDS virus and the resilient Mycobacterium tuberculosis. In Malaysia, it is approved by the Ministry of Health as being effective against the H1N1 virus.” In announcement 2, Holista included the following in its slide presentation. • Slide 2 “Simulation Global Flu Pandemic”. • Slide 10 & 11, “Lab findings”. • Slide 13, “Can NatShieldTM kill the HIN1 virus?” In respect to the above, the Company retracts the statements made in announcement 1 (or similar versions of the statements), as a result of not technically complying with the level of disclosure required in accordance with the ASX Biotech Code, “Code of best practice”, second edition. In respect to the above, the Company retracts the relevant slides and the information contained in those slides for announcement 2 (or similar versions of the statements), as a result of not technically complying with the level of disclosure required in accordance with the ASX Biotech Code, “Code of best practice”, second edition. Investors should not rely on the retracted information and slides for their investment decisions.
- Forums
- ASX - By Stock
- Ann: US Distributor for Natshield sanitiser appointed with sales
are you talking about the oh so wonderful sanitiser that the...
-
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add HCT (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.3¢ |
Change
-0.001(4.17%) |
Mkt cap ! $6.412M |
Open | High | Low | Value | Volume |
2.3¢ | 2.3¢ | 2.3¢ | $20 | 863 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 30000 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.3¢ | 184832 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 30000 | 0.019 |
1 | 508000 | 0.008 |
1 | 100000 | 0.006 |
2 | 435000 | 0.005 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.023 | 184832 | 1 |
0.027 | 80000 | 1 |
0.028 | 49999 | 1 |
0.029 | 78000 | 2 |
0.030 | 12000 | 1 |
Last trade - 10.04am 04/10/2024 (20 minute delay) ? |
Featured News
HCT (ASX) Chart |